Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Christopher R. Cline Sells 2,490 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Christopher R. Cline sold 2,490 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $11.52, for a total value of $28,684.80. Following the transaction, the chief financial officer now directly owns 74,595 shares of the company’s stock, valued at approximately $859,334.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Travere Therapeutics Price Performance

Travere Therapeutics stock opened at $12.24 on Thursday. The business has a 50 day simple moving average of $9.48 and a 200 day simple moving average of $7.92. The company has a debt-to-equity ratio of 24.96, a current ratio of 3.04 and a quick ratio of 2.99. The company has a market capitalization of $936.24 million, a PE ratio of -5.83 and a beta of 0.71. Travere Therapeutics, Inc. has a one year low of $5.12 and a one year high of $14.07.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). Travere Therapeutics had a negative net margin of 82.14% and a negative return on equity of 269.18%. The company had revenue of $54.12 million for the quarter, compared to the consensus estimate of $49.50 million. On average, sell-side analysts forecast that Travere Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Institutional Investors Weigh In On Travere Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Forefront Analytics LLC grew its holdings in shares of Travere Therapeutics by 10.2% during the second quarter. Forefront Analytics LLC now owns 13,317 shares of the company’s stock worth $109,000 after purchasing an additional 1,237 shares during the last quarter. ProShare Advisors LLC grew its holdings in Travere Therapeutics by 9.2% during the 1st quarter. ProShare Advisors LLC now owns 18,421 shares of the company’s stock worth $142,000 after acquiring an additional 1,557 shares during the last quarter. Rice Hall James & Associates LLC increased its position in Travere Therapeutics by 3.8% in the 2nd quarter. Rice Hall James & Associates LLC now owns 76,174 shares of the company’s stock valued at $626,000 after acquiring an additional 2,774 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Travere Therapeutics by 10.5% in the first quarter. Price T Rowe Associates Inc. MD now owns 31,009 shares of the company’s stock worth $240,000 after acquiring an additional 2,948 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Travere Therapeutics by 8.1% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 50,178 shares of the company’s stock worth $387,000 after purchasing an additional 3,754 shares in the last quarter.

Analyst Ratings Changes

TVTX has been the subject of a number of research analyst reports. Barclays upped their price target on Travere Therapeutics from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Bank of America upped their target price on shares of Travere Therapeutics from $18.00 to $19.00 and gave the company a “buy” rating in a research note on Friday, September 6th. Piper Sandler raised their price target on shares of Travere Therapeutics from $11.00 to $12.00 and gave the stock a “neutral” rating in a research report on Friday, August 2nd. Wedbush upped their price objective on shares of Travere Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, JPMorgan Chase & Co. boosted their price target on Travere Therapeutics from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Travere Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $17.33.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.